A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT) Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

Disclosures Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

Study Rationale Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

Study 303: Study Schema Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

Patient Characteristics Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

Primary Endpoint: Kaplan-Meier Estimate of PFS Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

PFS by Previous VEGF-Targeted Therapy Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

PFS Subgroup Analyses Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

Response Rates Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

Best Tumor Response Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

Overall Survival, ITT population Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

Study Medication Exposure Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

Treatment-emergent Adverse Events (TEAEs) Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

Most Frequent Treatment-related Adverse Events (> 20%) Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

TEAEs of Special Interest Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

Conclusions Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

Slide 17 Presented By Martin Schlumberger at 2014 ASCO Annual Meeting